Consultation process to set strategies for european medicines agency (EMA) is open
A public consultation process is open until September 4th (through an online survey) to modify and improve the draft of European Medicines Agencies Strategy for the next five years, a document originally prepared by the Heads of Medicines Agencies (HMA) network and the European Medicines Agency(EMA). The final version of the document will be made public by the end of the year after analysis the contribution made by interested parties.
The objective of this comprehensive plan is to guarantee the administration of safe and efficient medicines that satisfy the needs of the patients vis-à-vis the challenges posed by the improvements – continuously accelerating – in science, medicine, digital technology and globalization, as well as new threats to health, such as the recent COVID-19 pandemic. Based on those requirements that the drafting of the document has included patient organizations, consumers, and healthcare professionals.
The European Medicines Agencies Strategy for 2025 will have 6 strategic areas as priority: availability and accessibility of the medicines; data analytics; digital tools and digital transformation; innovation; resistance to antimicrobial and other emerging threats to health; challenges in the administration workflow and sustainability of the Network and operational excellence.
The future roadmap will be in line with the Pharmaceutical Strategy for Europe and will take into consideration some lessons learned from the combat of the COVID-19 pandemic.Back to News